Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Biomarker-Directed Therapy Could Lead to Undertreatment of Nonclonal Recurrent DCIS

April 10th 2022

Among patients with ductal carcinoma in situ, a significant portion of recurrences were not genetically related to the primary tumor.

Patient Profile 1: Frontline Therapy for HER2+ mBC

April 8th 2022

Centering discussion on a patient profile of HER2+ metastatic breast cancer, experts elucidate frontline therapy selection in this setting.

Recent Trial Data in HER2+ Metastatic Breast Cancer

April 8th 2022

Before moving on to the patient profiles, expert panelists review recent clinical trial data that have impacted treatment selection and sequencing in HER2+ metastatic breast cancer.

Tripathy on Treating HER2+ Breast Cancer With Leptomeningeal Metastasis

April 7th 2022

Dr Tripathy explains the rationale for the TBCRC049 trial, the challenges of investigating a disease that appears in less than 5% of patients with breast cancer, and potential avenues for future investigations.

Dr. Sammons on Findings From the EMERALD Trial in ER+ Advanced or Metastatic Breast Cancer

April 6th 2022

Sarah Sammons, MD, discusses findings from the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer.

State of Science Summit- Breast Cancer: Chaired by Reshma Mahtani, DO

April 4th 2022

State of Science Summit- Breast Cancer: Chaired by Reshma Mahtani, DO

Dr. George on Efforts to Address Unmet Needs in HER2-Low Breast Cancer

April 1st 2022

Mridula George, MD, discusses efforts to address unmet needs in HER2-low breast cancer.

Selecting and Sequencing Therapy for HER2+ Breast Cancer

April 1st 2022

Shared insight on the optimal sequencing of therapeutic agents for patients undergoing treatment for HER2+ metastatic breast cancer.

HER2+ Breast Cancer: Overview of the Treatment Armamentarium

April 1st 2022

Comprehensive insight on therapeutic classes and agents approved in the setting of HER2+ metastatic breast cancer, with a specific focus on how these therapies fit into current treatment strategies.

Clinical Advancements of Targeted Antibody-Drug Conjugates in Breast and Lung Cancer

March 31st 2022

This article surveils key advancements in the role of antibody-drug conjugates in solid tumors by examining important clinical trial findings on targeting Trop-2 in breast and lung cancers.

SERDs, ESR1 Mutations Dominate Updates in ER-Positive Breast Cancer

March 31st 2022

Sara A. Hurvitz, MD, FACP, led a panel of breast cancer experts—Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky, MD, MS—in a review of key data from the 2021 San Antonio Breast Cancer Symposium in ER-positive breast cancer.

New Treatment Standards Spark Questions About De-escalation and Sequencing in Breast Cancer

March 30th 2022

Sara M. Tolaney, MD, MPH, reviews practice-changing data sets throughout breast cancer and provides perspective on potential treatment approaches in the absence of definitive results.

Dr. Jhaveri on the TUXEDO-1 Trial in HER2+ Breast Cancer With Brain Metastases

March 23rd 2022

Komal Jhaveri, MD, FACP, discusses the implications of the phase 2 TUXEDO-1 trial in patients with HER2-positive metastatic breast cancer with brain metastases.

Dr. Traina on the Effects of Elacestrant in ER+, HER2- Breast Cancer

March 21st 2022

Tiffany A. Traina, MD, discusses the implications of the phase 3 EMERALD trial in advanced estrogen receptor–positive, HER2-negative breast cancer.

Dr. Jhaveri on Implications of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

March 21st 2022

Komal Jhaveri, MD, FACP, discusses the implications of data from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

Breast Cancer Treatment Advances Lead to Broadened Scope of Personalized Medicine

March 21st 2022

Harold J. Burstein, MD, PhD, discusses treatment updates across HER2-positive breast cancer, adjuvant advances in estrogen receptor–positive disease, and the domino effect of immunotherapy in triple-negative breast cancer.

Adjuvant Olaparib Significantly Improves OS in BRCA+, High-Risk Early Breast Cancer

March 17th 2022

At a median follow-up of 3.5 years, adjuvant olaparib significantly improved overall survival vs placebo in patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who received prior chemotherapy before or after surgery.

Institutional Perspectives in Cancer- Breast Cancer: Chaired by Angela DeMichele, MD, MSCE

March 17th 2022

Top 8 Trials From 2021 in Breast Cancer

March 16th 2022

Leading oncologists in breast cancer share their perspectives on the biggest abstracts that were presented throughout 2021 .

ESR1 Data Fuel Novel Breast Cancer Strategies

March 15th 2022

Mutations on the ESR1 gene, which encodes the estrogen receptor, have emerged as an important driver of resistance to endocrine therapies, which form the backbone of treatment for patients with ER-positive, HER2-negative breast cancer.